Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease

doi:10.1016/0304-3940(95)11323-O

Neuroscience Letters

Volume 187, Issue 1, 24 February 1995, Pages 5-8

https://doi.org/10.1016/0304-3940(95)11323-O Get rights and content

Abstract

Particulate and soluble guanylyl cyclase activities were studied in postmortem temporal cortex from a series of Alzheimer's disease patients and matched control subjects. Particulate guanylyl cyclase activity was not significantly different between groups. In contrast, the V_max values for basal and sodium nitroprusside-stimulated soluble guanylyl cyclase activities were approximately 50% lower in the Alzheimer's disease cases, compared to controls. This difference between groups was statistically significant for sodium nitroprusside-stimulated, but not for the basal, enzyme activities. These results provide the first evidence for a loss of nitric oxide responsive guanylyl cyclase activity in Alzheimer's disease brain.

References (21)

R. Cowburn et al.
Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease
Brain Res.
(1988)
E. Danielsson et al.
VIP-sensitive adenylate cyclase, guanylate cyclase, muscarinic receptors, choline acetyltransferase and acetylcholinesterase in brain tissue afflicted by Alzheimer's disease/senile dementia of the Alzheimer type
Neurobiol. Aging
(1988)
T. Furuyama et al.
Localizations of α1 and β1 subunits of soluble guanylate cyclase
Mol. Brain Res.
(1993)
J. Garthwaite
Glutamate, nitric oxide and cell-cell signaling in the nervous system
Trends Neurosci.
(1991)
M.A.K. Markwell et al.
A modification of the standard Lowry procedure to simplify protein determination in membranes and lipoprotein samples
Anal. Biochem.
(1978)
M. Nakane et al.
Light and electron microscopic demonstration of guanylate cyclase in rat brain
Brain Res.
(1983)
D.M. Bowen et al.
Alzheimer's disease: is the improvement of cholinergic transmission the correct strategy?
D.S. Bredt et al.
Nitric oxide mediates glutamatelinked enhancement of cGMP levels in the cerebellum
Cowburn R.F., Fowler, C.J. and O'Neill, C., Neurotransmitters, signal transduction and second messengers in Alzheimer's...
V.L. Dawson et al.
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures
J. Neurosci.
(1993)

There are more references available in the full text version of this article.

Cited by (75)

Biologic that disrupts PDE11A4 homodimerization in hippocampus CA1 reverses age-related cognitive decline of social memories in mice
2023, Neurobiology of Aging
Age-related abnormalities in phosphodiesterase 11A (PDE11A), which degrades 3′,5′-cAMP/cGMP and is enriched in the ventral hippocampus (VHIPP), drive age-related cognitive decline (ARCD) of social memories. Age-related PDE11A4 ectopically accumulates within the membrane compartment and in filamentous structures termed ghost axons. Previous studies show that expressing an isolated PDE11A4-GAF-B binding domain disrupts homodimerization and reverses aging-like PDE11A4 accumulations in vitro. Here, we show that in vivo lentiviral expression of the isolated PDE11A4-GAFB domain in hippocampal CA1 of aged mice reverses age-related PDE11A4 accumulations and ARCD of social transmission of food preference memory (STFP). It also improves 7-day remote long-term memory for social odor recognition without affecting non-social odor recognition. In vitro studies show that disrupting homodimerization does not alter the catalytic activity of PDE11A4 but may reverse age-related decreases in cGMP by relocating PDE11A4 from a cGMP-rich to a cAMP-rich pool independently of other intramolecular relocation signals (PDE11A4-pS162). Altogether, these data suggest that a biologic designed to disrupt PDE11A4 homodimerization may hold therapeutic potential for age-related PDE11A4 proteinopathies.
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer's disease
2022, Free Radical Biology and Medicine
Citation Excerpt :
Aβ also blocked the physiological increase in cGMP immunoreactivity occurring after LTP induction in murine hippocampal slices [77]. A decreased activity and/or expression of sGC was confirmed in superior temporal cortex of AD patients [89] and in reactive astrocytes obtained from cortical samples of AD brains [90]. Consistently, cGMP levels were reduced in cerebrospinal fluid (CSF) of AD patients compared with aged-matched controls and, interestingly, this reduction correlated with worse performances on the Mini Mental State Examination [91,92].
The nitric oxide (NO)/cGMP pathway has been extensively studied for its pivotal role in synaptic plasticity and memory processes, resulting in an increase of cAMP response element-binding (CREB) phosphorylation, and consequent synthesis of plasticity-related proteins. The NO/cGMP/CREB signaling is downregulated during aging and neurodegenerative disorders and is affected by Amyloid-β peptide (Aβ) and tau protein, whose increase and deposition is considered the key pathogenic event of Alzheimer's disease (AD). On the other hand, in physiological conditions, the crosstalk between the NO/cGMP/PKG/CREB pathway and Aβ ensures long-term potentiation and memory formation.
This review summarizes the current knowledge on the interaction between the NO/cGMP/PKG/CREB pathway and Aβ in the healthy and diseased brain, offering a new perspective to shed light on AD pathophysiology. We will focus on the synaptic mechanisms underlying Aβ physiological interplay with cGMP pathway and how this balance is corrupted in AD, as high levels of Aβ interfere with NO production and cGMP molecular signaling leading to cognitive impairment.
Finally, we will discuss results from preclinical and clinical studies proposing the increase of cGMP signaling as a therapeutic strategy in the treatment of AD.
Alterations in cyclic nucleotide signaling are implicated in healthy aging and age-related pathologies of the brain
2021, Vitamins and Hormones
Citation Excerpt :
One proposed mechanism suggests NOS signaling may increase in response to the downregulation of sGC activity/expression in AD. In the superior temporal cortex of AD patients, a decrease in sGC activity- but not pGC- was identified (Bonkale, Winblad, Ravid, & Cowburn, 1995). Reactive astrocytes of AD patients (Baltrons, Pifarre, Ferrer, Carot, & Garcia, 2004) and Aβ1–40- or Aβ25–35-treated cultured astrocytes saw a similar decrease in sGC activity and/or expression (Baltrons, Pedraza, Heneka, & Garcia, 2002).
It is not only important to consider how hormones may change with age, but also how downstream signaling pathways that couple to hormone receptors may change. Among these hormone-coupled signaling pathways are the 3′,5′-cyclic guanosine monophosphate (cGMP) and 3′,5′-cyclic adenosine monophosphate (cAMP) intracellular second messenger cascades. Here, we test the hypothesis that dysfunction of cAMP and/or cGMP synthesis, execution, and/or degradation occurs in the brain during healthy and pathological diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Although most studies report lower cyclic nucleotide signaling in the aged brain, with further reductions noted in the context of age-related diseases, there are select examples where cAMP signaling may be elevated in select tissues. Thus, therapeutics would need to target cAMP/cGMP in a tissue-specific manner if efficacy for select symptoms is to be achieved without worsening others.
Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot
2020, Neuroscience and Biobehavioral Reviews
A plethora of studies indicate the important role of cAMP and cGMP cascades in neuronal plasticity and memory function. As a result, altered cyclic nucleotide signaling has been implicated in the pathophysiology of mnemonic dysfunction encountered in several diseases. In the present review we provide a wide overview of studies regarding the involvement of cyclic nucleotides, as well as their upstream and downstream molecules, in physiological and pathological mnemonic processes. Next, we discuss the regulation of the intracellular concentration of cyclic nucleotides via phosphodiesterases, the enzymes that degrade cAMP and/or cGMP, and via A-kinase-anchoring proteins that refine signal compartmentalization of cAMP signaling. We also provide an overview of the available data pointing to the existence of specific time windows in cyclic nucleotide signaling during neuroplasticity and memory formation and the significance to target these specific time phases for improving memory formation. Finally, we highlight the importance of emerging imaging tools like Förster resonance energy transfer imaging and optogenetics in detecting, measuring and manipulating the action of cyclic nucleotide signaling cascades.
Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span
2018, Neurobiology of Aging
Citation Excerpt :
It has yet to be reported which pools of cGMP are regulated by PDE9A in the brain. Given that diseases such as Alzheimer's disease have been associated with subcellular compartment–specific deficits in cGMP signaling (Bonkale et al., 1995; Kelly, 2018), it is important to address this gap in knowledge. As such, this study aims to identify (1) the subcellular localization of PDE9 isoforms in the brain; and (2) how PDE9 expression and subcellular localization of PDE9A may change across the life span.
3′,5′-Cyclic nucleotide phosphodiesterases (PDEs) degrade 3′,5′ cyclic adenonosine monophosphate (cAMP) and 3′,5′ cyclic guanosine monophosphate (cGMP), with PDE9A having the highest affinity for cGMP. We show PDE9A6 and 3 novel PDE9 isoforms (PDE9X-100, PDE9X-120, and PDE9X-175) are reliably detected in the brain and lung of mice, whereas PDE9A2 and other isoforms are found elsewhere. PDE9A localizes to the membrane in all organs except the bladder, where it is cytosolic. Brain additionally shows PDE9 in the nuclear fraction. PDE9A mRNA expression/localization dramatically changes across neurodevelopment in a manner that is strikingly consistent between mice and humans (i.e., decreased expression in the hippocampus and cortex and inverted-U in the cerebellum). Study of the 4 PDE9 isoforms in the mouse brain from postnatal day 7 through 24 months similarly identifies dramatic effects of age on expression and subcellular compartmentalization that are isoform specific and brain region specific. Finally, PDE9A mRNA is elevated in the aged human hippocampus with dementia when there is a history of traumatic brain injury. Thus, brain PDE9 is localized to preferentially regulate nuclear- and membrane-proximal pools of cGMP, and its function likely changes across the life span.
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain
2018, Cellular Signalling
Citation Excerpt :
These increases in NOS signaling may reflect a compensatory change in response to reduced expression and/or activity of sGCs. Indeed, decreased activity of sGC—but not pGC—was noted in superior temporal cortex of AD patients [198] and decreased activity and/or expression of sGC was noted in reactive astrocytes of AD patients [199] and cultured astrocytes treated with Aβ1-40 or Aβ25-35 [200]. Consistent with the idea that AD is associated with a loss of sGC signaling, cGMP levels are significantly reduced in CSF of AD patients vs. age-matched controls, and lower CSF cGMP levels significantly correlate with worsening performance on the mini mental state exam (MMSE) [141,142] (but see [143]).
Deficits in brain function that are associated with aging and age-related diseases benefit very little from currently available therapies, suggesting a better understanding of the underlying molecular mechanisms is needed to develop improved drugs. Here, we review the literature to test the hypothesis that a break down in cyclic nucleotide signaling at the level of synthesis, execution, and/or degradation may contribute to these deficits. A number of findings have been reported in both the human and animal model literature that point to brain region-specific changes in Galphas (a.k.a. Gαs or Gsα), adenylyl cyclase, 3′,5′-adenosine monophosphate (cAMP) levels, protein kinase A (PKA), cAMP response element binding protein (CREB), exchange protein activated by cAMP (Epac), hyperpolarization-activated cyclic nucleotide-gated ion channels (HCNs), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), soluble and particulate guanylyl cyclase, 3′,5′-guanosine monophosphate (cGMP), protein kinase G (PKG) and phosphodiesterases (PDEs). Among the most reproducible findings are 1) elevated circulating ANP and BNP levels being associated with cognitive dysfunction or dementia independent of cardiovascular effects, 2) reduced basal and/or NMDA-stimulated cGMP levels in brain with aging or Alzheimer's disease (AD), 3) reduced adenylyl cyclase activity in hippocampus and specific cortical regions with aging or AD, 4) reduced expression/activity of PKA in temporal cortex and hippocampus with AD, 5) reduced phosphorylation of CREB in hippocampus with aging or AD, 6) reduced expression/activity of the PDE4 family in brain with aging, 7) reduced expression of PDE10A in the striatum with Huntington's disease (HD) or Parkinson's disease, and 8) beneficial effects of select PDE inhibitors, particularly PDE10 inhibitors in HD models and PDE4 and PDE5 inhibitors in aging and AD models. Although these findings generally point to a reduction in cyclic nucleotide signaling being associated with aging and age-related diseases, there are exceptions. In particular, there is evidence for increased cAMP signaling specifically in aged prefrontal cortex, AD cerebral vessels, and PD hippocampus. Thus, if cyclic nucleotide signaling is going to be targeted effectively for therapeutic gain, it will have to be manipulated in a brain region-specific manner.

View all citing articles on Scopus

View full text

Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease

Abstract

Brain Res.

Neurobiol. Aging

Mol. Brain Res.

Trends Neurosci.

Anal. Biochem.

Brain Res.

Alzheimer's disease: is the improvement of cholinergic transmission the correct strategy?

Nitric oxide mediates glutamatelinked enhancement of cGMP levels in the cerebellum

Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures

J. Neurosci.